Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Fosamax (02201038), Co Alendronate (02258102). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
ALENDRONATE
19 general benefit · 5 not a benefit
Other products in the same Health Canada class (M05B, M05BA) — coverage varies; not interchangeable
- Risedronate (Actonel DR): general benefit, Not a benefit
- Clodronate (Ostac): limited Use 280, 358, 359, Not a benefit
- Etidronate (Didronel): limited Use 236, 237, Not a benefit
- Zoledronic acid (Aclasta): limited Use 319, 436, 523, Not a benefit
- Pamidronate (Aredia): not a benefit
- Denosumab (Stoboclo): limited Use 686, Limited Use 687, 688
Alendronate Sodium Tablets · DIN 02381486 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Alendronate Sodium Tablets · DIN 02381486
Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26
Health Canada: Marketed since 2012-03-20 · brand ACH-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Accord healthcare inc · schedule Prescription
Alendronate Sodium Tablets: Formulary list price $0.4987/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4987 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86733 · Verify on the e-Formulary ↗ (DIN 02381486)
Source record
DIN 02381486: Alendronate Sodium Tablets
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000232; group id 891; item number 2140; lccId None; manufacturer id ACH
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4987; ministry $0.4987
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381486
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86733
Interchangeable products
Apo-Alendronate · DIN 02248728 · $0.4987
Auro-Alendronate · DIN 02388545 · $0.4987
Fosamax · DIN 02201011 · not recorded
Mint-Alendronate · DIN 02394863 · $0.4987
Ran-Alendronate · DIN 02384701 · $0.4987
Sandoz Alendronate · DIN 02288087 · $0.4987
Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: active shortage (reported 2024-04-12, last updated 2024-04-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381486
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Alendronate · DIN 02388545 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Alendronate · DIN 02388545
Manufacturer: Auro Pharma Inc.; listing date 2012-09-28
Health Canada: Marketed since 2012-07-26 · brand AURO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Auro pharma inc · schedule Prescription
Auro-Alendronate: Formulary list price $0.4987/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4987 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87407 · Verify on the e-Formulary ↗ (DIN 02388545)
Source record
DIN 02388545: Auro-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000232; group id 891; item number 2140; lccId None; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4987; ministry $0.4987
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388545
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87407
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987
Apo-Alendronate · DIN 02248728 · $0.4987
Fosamax · DIN 02201011 · not recorded
Mint-Alendronate · DIN 02394863 · $0.4987
Ran-Alendronate · DIN 02384701 · $0.4987
Sandoz Alendronate · DIN 02288087 · $0.4987
Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: resolved shortage (ended 2024-10-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388545
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Alendronate · DIN 02299712 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Alendronate · DIN 02299712
Manufacturer: Sivem Pharmaceuticals ULC; listing date 2009-11-19
Health Canada: Marketed since 2022-01-27 · brand ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78508 · Verify on the e-Formulary ↗ (DIN 02299712)
Source record
DIN 02299712: Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id SIV
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02299712
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78508
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2023-04-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02299712
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Alendronate · DIN 02352966 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Alendronate · DIN 02352966
Manufacturer: Sanis Health Inc.; listing date 2011-08-04
Health Canada: Marketed since 2026-02-25 · brand ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Sanis health inc · schedule Prescription
Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83819 · Verify on the e-Formulary ↗ (DIN 02352966)
Source record
DIN 02352966: Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id SAI
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02352966
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83819
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2026-04-25); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02352966
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Alendronate Sodium Tablets · DIN 02381494 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Alendronate Sodium Tablets · DIN 02381494
Manufacturer: Accord Healthcare Inc.; listing date 2012-06-26
Health Canada: Marketed since 2012-03-20 · brand ACH-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Accord healthcare inc · schedule Prescription
Alendronate Sodium Tablets: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86734 · Verify on the e-Formulary ↗ (DIN 02381494)
Source record
DIN 02381494: Alendronate Sodium Tablets
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id ACH
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381494
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86734
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2026-02-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381494
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Alendronate · DIN 02248730 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Apo-Alendronate · DIN 02248730
Manufacturer: Apotex Inc.; listing date 2005-07-14
Health Canada: Marketed since 2005-05-27 · brand APO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Apotex inc · schedule Prescription
Apo-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73098 · Verify on the e-Formulary ↗ (DIN 02248730)
Source record
DIN 02248730: Apo-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id APX
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248730
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73098
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2023-10-19); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248730
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Alendronate · DIN 02388553 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Auro-Alendronate · DIN 02388553
Manufacturer: Auro Pharma Inc.; listing date 2012-09-28
Health Canada: Marketed since 2012-07-26 · brand AURO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Auro pharma inc · schedule Prescription
Auro-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87408 · Verify on the e-Formulary ↗ (DIN 02388553)
Source record
DIN 02388553: Auro-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id AUR
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388553
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87408
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2024-07-16); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02388553
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Fosamax · DIN 02245329 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fosamax · DIN 02245329
Manufacturer: Organon Canada Inc.; listing date 2003-01-30
Health Canada: Marketed since 2022-05-03 · brand FOSAMAX · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Organon canada inc. · schedule Prescription
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69356 · Verify on the e-Formulary ↗ (DIN 02245329)
Source record
DIN 02245329: Fosamax
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id OCI
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $12.6250; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245329
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69356
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02245329
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Jamp Alendronate Sodium · DIN 02500175 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp Alendronate Sodium · DIN 02500175
Manufacturer: Jamp Pharma Corporation; listing date 2022-09-29
Health Canada: Marketed since 2022-07-22 · brand JAMP ALENDRONATE SODIUM · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Jamp pharma corporation · schedule Prescription
Jamp Alendronate Sodium: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98988 · Verify on the e-Formulary ↗ (DIN 02500175)
Source record
DIN 02500175: Jamp Alendronate Sodium
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id JPC
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02500175
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=98988
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02500175
Shortage record checked 2026-09-13T08:10:21.292534+00:00
M-Alendronate · DIN 02529394 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
M-Alendronate · DIN 02529394
Manufacturer: Mantra Pharma Inc.; listing date 2023-06-30
Health Canada: Marketed since 2026-06-29 · brand M-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Mantra pharma inc · schedule Prescription
M-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101860 · Verify on the e-Formulary ↗ (DIN 02529394)
Source record
DIN 02529394: M-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id MAT
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02529394
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101860
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02529394
Shortage record checked 2026-09-13T08:10:21.292534+00:00
NRA-Alendronate · DIN 02523116 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
NRA-Alendronate · DIN 02523116
Manufacturer: Nora Pharma; listing date 2022-11-30
Health Canada: Marketed since 2022-08-09 · brand NRA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Nora pharma inc · schedule Prescription
NRA-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101218 · Verify on the e-Formulary ↗ (DIN 02523116)
Source record
DIN 02523116: NRA-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id NRA
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02523116
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101218
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2026-05-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02523116
Shortage record checked 2026-09-13T08:10:21.292534+00:00
PMS-Alendronate-FC · DIN 02284006 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
PMS-Alendronate-FC · DIN 02284006
Manufacturer: Pharmascience Inc.; listing date 2007-03-09
Health Canada: Marketed since 2006-08-15 · brand PMS-ALENDRONATE-FC · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Pharmascience inc · schedule Prescription
PMS-Alendronate-FC: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76957 · Verify on the e-Formulary ↗ (DIN 02284006)
Source record
DIN 02284006: PMS-Alendronate-FC
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id PMS
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02284006
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76957
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2024-11-26); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02284006
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Riva-Alendronate · DIN 02270889 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Riva-Alendronate · DIN 02270889
Manufacturer: Laboratoire Riva Inc.; listing date 2021-08-31
Health Canada: Marketed since 2025-12-09 · brand RIVA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Laboratoire riva inc. · schedule Prescription
Riva-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75626 · Verify on the e-Formulary ↗ (DIN 02270889)
Source record
DIN 02270889: Riva-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id RIA
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02270889
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75626
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2024-01-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02270889
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Teva-Alendronate · DIN 02261715 · 70mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Teva-Alendronate · DIN 02261715
Manufacturer: Teva Canada Limited; listing date 2005-08-19
Health Canada: Marketed since 2010-06-17 · brand TEVA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Teva canada limited · schedule Prescription
Teva-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74709 · Verify on the e-Formulary ↗ (DIN 02261715)
Source record
DIN 02261715: Teva-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id TEV
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02261715
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=74709
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Shortage status: resolved shortage (ended 2023-12-06); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02261715
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Alendronate Sodium Tablets · DIN 02381478 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Alendronate Sodium Tablets · DIN 02381478
Manufacturer: Accord Healthcare Inc.; listing date 2012-08-27
Health Canada: Marketed since 2012-03-20 · brand ACH-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Accord healthcare inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86732 · Verify on the e-Formulary ↗ (DIN 02381478)
Source record
DIN 02381478: Alendronate Sodium Tablets
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000294; group id 891; item number 2139; lccId None; manufacturer id ACH
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0370; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02381478
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86732
Interchangeable products
Apo-Alendronate · DIN 02248727 · not recorded
Fosamax · DIN 02233055 · not recorded
Teva-Alendronate · DIN 02248251 · not recorded
Shortage status: active shortage (reported 2024-07-12, last updated 2024-07-13) — report may be stale, confirm; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02381478
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Apo-Alendronate · DIN 02248728 · 10mg · tablet
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Alendronate · DIN 02248728
Manufacturer: Apotex Inc.; listing date 2004-07-20
Health Canada: Dormant since 2021-03-16 · brand APO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Apotex inc · schedule Prescription
Apo-Alendronate: Formulary list price $0.4987/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4987 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73096 · Verify on the e-Formulary ↗ (DIN 02248728)
Source record
DIN 02248728: Apo-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000232; group id 891; item number 2140; lccId None; manufacturer id APX
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4987; ministry $0.4987
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248728
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73096
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987
Auro-Alendronate · DIN 02388545 · $0.4987
Fosamax · DIN 02201011 · not recorded
Mint-Alendronate · DIN 02394863 · $0.4987
Ran-Alendronate · DIN 02384701 · $0.4987
Sandoz Alendronate · DIN 02288087 · $0.4987
Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248728
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-03-16 — choose a marketed DIN from the same-category list.
AG-Alendronate · DIN 02485184 · 70mg · tablet
General benefitDormant since 2025-07-30 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
AG-Alendronate · DIN 02485184
Manufacturer: Angita Pharma Inc.; listing date 2020-11-30
Health Canada: Dormant since 2025-07-30 · brand AG-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Angita pharma inc. · schedule Prescription
AG-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97543 · Verify on the e-Formulary ↗ (DIN 02485184)
Source record
DIN 02485184: AG-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id ANG
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485184
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97543
Interchangeable products
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02485184
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-07-30 — choose a marketed DIN from the same-category list.
Jamp-Alendronate · DIN 02385031 · 70mg · tablet
General benefitDormant since 2024-07-31 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Jamp-Alendronate · DIN 02385031
Manufacturer: Jamp Pharma Corporation; listing date 2012-09-28
Health Canada: Dormant since 2024-07-31 · brand JAMP-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70 MG · company Jamp pharma corporation · schedule Prescription
Jamp-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87070 · Verify on the e-Formulary ↗ (DIN 02385031)
Source record
DIN 02385031: Jamp-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id JPC
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385031
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87070
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
Mint-Alendronate · DIN 02394871 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: resolved shortage (ended 2024-04-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02385031
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2024-07-31 — choose a marketed DIN from the same-category list.
Mint-Alendronate · DIN 02394871 · 70mg · tablet
General benefitDormant since 2025-09-12 · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)1 brand, same coverage
Mint-Alendronate · DIN 02394871
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-03-20
Health Canada: Dormant since 2025-09-12 · brand MINT-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 70.0 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Alendronate: Formulary list price $1.7804/unit (unit not stated in source; not the patient's cost)
Ministry pays: $1.7804 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88003 · Verify on the e-Formulary ↗ (DIN 02394871)
Source record
DIN 02394871: Mint-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000426; group id 891; item number 2141; lccId None; manufacturer id MIN
Source form: Tab; strength: 70mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $1.7804; ministry $1.7804
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394871
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88003
Interchangeable products
AG-Alendronate · DIN 02485184 · $1.7804
Alendronate · DIN 02299712 · $1.7804
Alendronate · DIN 02352966 · $1.7804
Alendronate Sodium Tablets · DIN 02381494 · $1.7804
Apo-Alendronate · DIN 02248730 · $1.7804
Auro-Alendronate · DIN 02388553 · $1.7804
Fosamax · DIN 02245329 · $1.7804
Jamp Alendronate Sodium · DIN 02500175 · $1.7804
Jamp-Alendronate · DIN 02385031 · $1.7804
M-Alendronate · DIN 02529394 · $1.7804
NRA-Alendronate · DIN 02523116 · $1.7804
PMS-Alendronate-FC · DIN 02284006 · $1.7804
Riva-Alendronate · DIN 02270889 · $1.7804
Sandoz Alendronate · DIN 02288109 · $1.7804
Teva-Alendronate · DIN 02261715 · $1.7804
Shortage status: active shortage (reported 2024-01-18, estimated to end 2026-06-30, last updated 2026-06-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394871
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2025-09-12 — choose a marketed DIN from the same-category list.
Apo-Alendronate · DIN 02248727 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefitDormant since 2021-07-07 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Alendronate · DIN 02248727
Manufacturer: Apotex Inc.; listing date 2007-10-03
Health Canada: Dormant since 2021-07-07 · brand APO-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Apotex inc · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73095 · Verify on the e-Formulary ↗ (DIN 02248727)
Source record
DIN 02248727: Apo-Alendronate
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000294; group id 891; item number 2139; lccId None; manufacturer id APX
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0370; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248727
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73095
Interchangeable products
Alendronate Sodium Tablets · DIN 02381478 · not recorded
Fosamax · DIN 02233055 · not recorded
Teva-Alendronate · DIN 02248251 · not recorded
Shortage status: discontinued (2019-12-20, reported by APOTEX INC); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248727
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Dormant since 2021-07-07 — choose a marketed DIN from the same-category list.
Mint-Alendronate · DIN 02394863 · 10mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.Discontinued 2018-08-01 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Mint-Alendronate · DIN 02394863
Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-03-20
Health Canada: Cancelled post market since 2018-08-01 · brand MINT-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10.0 MG · company Mint pharmaceuticals inc · schedule Prescription
Mint-Alendronate: Formulary list price $0.4987/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.4987 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88002 · Verify on the e-Formulary ↗ (DIN 02394863)
Source record
DIN 02394863: Mint-Alendronate
Raw flags: chronicUseMed=Y, sec3=Y
Item: 920000232; group id 891; item number 2140; lccId None; manufacturer id MIN
Source form: Tab; strength: 10mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.4987; ministry $0.4987
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02394863
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88002
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987
Apo-Alendronate · DIN 02248728 · $0.4987
Auro-Alendronate · DIN 02388545 · $0.4987
Fosamax · DIN 02201011 · not recorded
Ran-Alendronate · DIN 02384701 · $0.4987
Sandoz Alendronate · DIN 02288087 · $0.4987
Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02394863
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2018-08-01 — choose a marketed DIN from the same-category list.
Fosamax · DIN 02233055 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-30 — choose a marketed DIN from the same-category list.Discontinued 2010-07-30 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-30 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-07-30 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fosamax · DIN 02233055
Manufacturer: Merck Frosst Canada Ltd.; listing date 2007-10-03
Health Canada: Cancelled post market since 2010-07-30 · brand FOSAMAX · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Merck canada inc · schedule Prescription
Fosamax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52648 · Verify on the e-Formulary ↗ (DIN 02233055)
Source record
DIN 02233055: Fosamax
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000294; group id 891; item number 2139; lccId None; manufacturer id MFC
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02233055
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=52648
Interchangeable products
Alendronate Sodium Tablets · DIN 02381478 · not recorded
Apo-Alendronate · DIN 02248727 · not recorded
Teva-Alendronate · DIN 02248251 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02233055
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2010-07-30 — choose a marketed DIN from the same-category list.
Teva-Alendronate · DIN 02248251 · 5mg · tablet
Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.Discontinued 2021-07-29 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Alendronate · DIN 02248251
Manufacturer: Teva Canada Limited; listing date 2007-10-03
Health Canada: Cancelled post market since 2021-07-29 · brand TEVA-ALENDRONATE · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 5 MG · company Teva canada limited · schedule Prescription
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72588 · Verify on the e-Formulary ↗ (DIN 02248251)
Source record
DIN 02248251: Teva-Alendronate
Raw flags: notABenefit=Y, sec3=Y, sec3b=Y
Item: 920000294; group id 891; item number 2139; lccId None; manufacturer id TEV
Source form: Tab; strength: 5mg
Recorded listing: Off-Formulary Interchangeable, not an ODB benefit
Source prices (unrounded): $1.0370; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02248251
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=72588
Interchangeable products
Alendronate Sodium Tablets · DIN 02381478 · not recorded
Apo-Alendronate · DIN 02248727 · not recorded
Fosamax · DIN 02233055 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02248251
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-07-29 — choose a marketed DIN from the same-category list.
Fosamax · DIN 02201011 · 10mg · tablet
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-11-10 — choose a marketed DIN from the same-category list.Discontinued 2011-11-10 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2011-11-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2011-11-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Fosamax · DIN 02201011
Manufacturer: Merck Frosst Canada Ltd.; listing date 2000-11-30
Health Canada: Cancelled post market since 2011-11-10 · brand FOSAMAX · ATC M05BA04 ALENDRONIC ACID · form Tablet · route Oral · ingredients ALENDRONIC ACID (ALENDRONATE SODIUM) 10 MG · company Merck canada inc · schedule Prescription
Fosamax: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19643 · Verify on the e-Formulary ↗ (DIN 02201011)
Source record
DIN 02201011: Fosamax
Raw flags: chronicUseMed=Y, notABenefit=Y, sec3=Y
Item: 920000232; group id 891; item number 2140; lccId None; manufacturer id MFC
Source form: Tab; strength: 10mg
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02201011
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=19643
Interchangeable products
Alendronate Sodium Tablets · DIN 02381486 · $0.4987
Apo-Alendronate · DIN 02248728 · $0.4987
Auro-Alendronate · DIN 02388545 · $0.4987
Mint-Alendronate · DIN 02394863 · $0.4987
Ran-Alendronate · DIN 02384701 · $0.4987
Sandoz Alendronate · DIN 02288087 · $0.4987
Teva-Alendronate · DIN 02247373 · $0.4987
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02201011
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2011-11-10 — choose a marketed DIN from the same-category list.